Literature DB >> 23775727

Determination of 35 cell surface antigen levels in malignant pleural effusions identifies CD24 as a marker of disseminated tumor cells.

Xiaosai Yao1, Myriam Labelle, Carla R Lamb, John M Dugan, Christina A Williamson, Donna R Spencer, Kimberly R Christ, Ryan O Keating, W David Lee, Glenn A Paradis, Shahinoor Begum, Richard O Hynes, K Dane Wittrup.   

Abstract

Many targets have been identified in solid tumors for antibody therapy but it is less clear what surface antigens may be most commonly expressed on disseminated tumor cells. Using malignant pleural effusions as a source of disseminated tumor cells, we compared a panel of 35 antigens for their cancer specificity, antigen abundance and functional significance. These antigens have been previously implicated in cancer metastasis and fall into four categories: (i) cancer stem cell, (ii) epithelial-mesenchymal transition, (iii) metastatic signature of in vivo selection and (iv) tyrosine kinase receptors. We determined the antigen density of all 35 antigens on the cell surface by flow cytometry, which ranges from 3 × 10(3) -7 × 10(6) copies per cell. Comparison between the malignant and benign pleural effusions enabled us to determine the antigens specific for cancer. We further chose six antigens and examined the correlation between their expression levels and tumor formation in immunocompromised mice. We concluded that CD24 is one of the few antigens that could simultaneously meet all three criteria of an ideal target. It was specifically and abundantly expressed in malignant pleural effusions; CD24(high) tumor cells formed tumors in mice at a faster rate than CD24(low) tumor cells, and shRNA-mediated knockdown of CD24 in HT29 cells confirmed a functional requirement for CD24 in the colonization of the lung. Concomitant consideration of antigen abundance, specificity and functional importance can help identify potentially useful markers for disseminated tumor cells.
Copyright © 2013 UICC.

Entities:  

Keywords:  CD24; disseminated tumor cells; flow cytometry; pleural effusions; surface biomarker

Mesh:

Substances:

Year:  2013        PMID: 23775727      PMCID: PMC4107365          DOI: 10.1002/ijc.28312

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  27 in total

Review 1.  Monoclonal antibody therapy of cancer.

Authors:  Gregory P Adams; Louis M Weiner
Journal:  Nat Biotechnol       Date:  2005-09       Impact factor: 54.908

Review 2.  Identification and validation of cell surface antigens for antibody targeting in oncology.

Authors:  Paul Carter; Leia Smith; Maureen Ryan
Journal:  Endocr Relat Cancer       Date:  2004-12       Impact factor: 5.678

3.  Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.

Authors:  Birgit Schoeberl; Emily A Pace; Jonathan B Fitzgerald; Brian D Harms; Lihui Xu; Lin Nie; Bryan Linggi; Ashish Kalra; Violette Paragas; Raghida Bukhalid; Viara Grantcharova; Neeraj Kohli; Kip A West; Magdalena Leszczyniecka; Michael J Feldhaus; Arthur J Kudla; Ulrik B Nielsen
Journal:  Sci Signal       Date:  2009-06-30       Impact factor: 8.192

Review 4.  Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis.

Authors:  Q-L Liang; H-Z Shi; X-J Qin; X-D Liang; J Jiang; H-B Yang
Journal:  Thorax       Date:  2007-06-15       Impact factor: 9.139

Review 5.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions.

Authors:  Jane E Visvader; Geoffrey J Lindeman
Journal:  Nat Rev Cancer       Date:  2008-09-11       Impact factor: 60.716

6.  The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer.

Authors:  Steven C Smith; Gary Oxford; Zhong Wu; Matthew D Nitz; Mark Conaway; Henry F Frierson; Garret Hampton; Dan Theodorescu
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

7.  The epithelial-mesenchymal transition generates cells with properties of stem cells.

Authors:  Sendurai A Mani; Wenjun Guo; Mai-Jing Liao; Elinor Ng Eaton; Ayyakkannu Ayyanan; Alicia Y Zhou; Mary Brooks; Ferenc Reinhard; Cheng Cheng Zhang; Michail Shipitsin; Lauren L Campbell; Kornelia Polyak; Cathrin Brisken; Jing Yang; Robert A Weinberg
Journal:  Cell       Date:  2008-05-16       Impact factor: 41.582

8.  Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA.

Authors:  Eyal Sagiv; Alex Starr; Uri Rozovski; Rami Khosravi; Peter Altevogt; Timothy Wang; Nadir Arber
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

9.  Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer.

Authors:  Patrick C Hermann; Stephan L Huber; Tanja Herrler; Alexandra Aicher; Joachim W Ellwart; Markus Guba; Christiane J Bruns; Christopher Heeschen
Journal:  Cell Stem Cell       Date:  2007-09-13       Impact factor: 24.633

10.  Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.

Authors:  M Alimandi; A Romano; M C Curia; R Muraro; P Fedi; S A Aaronson; P P Di Fiore; M H Kraus
Journal:  Oncogene       Date:  1995-05-04       Impact factor: 9.867

View more
  8 in total

1.  Multi-MHz laser-scanning single-cell fluorescence microscopy by spatiotemporally encoded virtual source array.

Authors:  Jianglai Wu; Anson H L Tang; Aaron T Y Mok; Wenwei Yan; Godfrey C F Chan; Kenneth K Y Wong; Kevin K Tsia
Journal:  Biomed Opt Express       Date:  2017-08-21       Impact factor: 3.732

2.  Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis.

Authors:  Allison N Lau; Stephen J Curtis; Christine M Fillmore; Samuel P Rowbotham; Morvarid Mohseni; Darcy E Wagner; Alexander M Beede; Daniel T Montoro; Kerstin W Sinkevicius; Zandra E Walton; Juliana Barrios; Daniel J Weiss; Fernando D Camargo; Kwok-Kin Wong; Carla F Kim
Journal:  EMBO J       Date:  2014-02-04       Impact factor: 11.598

Review 3.  Squamous cell carcinoma of the oral cavity and circulating tumour cells.

Authors:  Johannes Wikner; Alexander Gröbe; Klaus Pantel; Sabine Riethdorf
Journal:  World J Clin Oncol       Date:  2014-05-10

4.  Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer.

Authors:  Tiyasha H Ayub; Mignon-Denise Keyver-Paik; Manuel Debald; Babak Rostamzadeh; Thore Thiesler; Lars Schröder; Winfried Barchet; Alina Abramian; Christina Kaiser; Glen Kristiansen; Walther Kuhn; Kirsten Kübler
Journal:  Oncotarget       Date:  2015-06-30

5.  Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.

Authors:  Joshua D Freedman; Joachim Hagel; Eleanor M Scott; Ioannis Psallidas; Avinash Gupta; Laura Spiers; Paul Miller; Nikolaos Kanellakis; Rebecca Ashfield; Kerry D Fisher; Margaret R Duffy; Leonard W Seymour
Journal:  EMBO Mol Med       Date:  2017-08       Impact factor: 12.137

6.  Fibronectin Modulates Cell Adhesion and Signaling to Promote Single Cell Migration of Highly Invasive Oral Squamous Cell Carcinoma.

Authors:  Grasieli de Oliveira Ramos; Lisiane Bernardi; Isabel Lauxen; Manoel Sant'Ana Filho; Alan Rick Horwitz; Marcelo Lazzaron Lamers
Journal:  PLoS One       Date:  2016-03-15       Impact factor: 3.240

7.  Engineering a high-affinity humanized anti-CD24 antibody to target hepatocellular carcinoma by a novel CDR grafting design.

Authors:  Fumou Sun; Tong Wang; Jiahao Jiang; Yang Wang; Zhaoxiong Ma; Zhaoting Li; Yue Han; Mingzhu Pan; Jialing Cai; Min Wang; Juan Zhang
Journal:  Oncotarget       Date:  2017-04-19

Review 8.  The Complexities of Metastasis.

Authors:  Beatriz P San Juan; Maria J Garcia-Leon; Laura Rangel; Jacky G Goetz; Christine L Chaffer
Journal:  Cancers (Basel)       Date:  2019-10-16       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.